What is claimed is:

1. A δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compound of formula (I)

$$\begin{array}{c|c}
 & OH & R^8 \\
 & R^7 \\
 & R^9 \\
 & R^3 \\
 & R^4 \\
 & R^5 \\
 & R^6
\end{array}$$
(I)

wherein

- R¹ is hydrogen, halogen, optionally halogenated alkyl, cycloalkyl, hydroxy, optionally halogenated alkoxy, cycloalkoxy, lower alkoxy-lower alkoxy or free or esterified or amidated carboxy-lower alkoxy or lower alkyl;
- R² is hydrogen, halogen, optionally halogenated lower alkyl, hydroxy, cycloalkyl, cycloalkoxy, optionally halogenated lower alkoxy-lower alkyl, optionally substituted lower alkoxy-lower alkyl, cycloalkoxy-lower alkyl; optionally lower alkanoylated, halogenated or sulfonylated hydroxy-lower alkoxy; amino-lower alkyl that is unsubstituted or substituted by lower alkyl, by lower alkanoyl and/or by lower alkoxycarbonyl, optionally hydrogenated heteroaryl-lower alkyl, amino-lower alkoxy that is substituted by lower alkyl, by lower alkanoyl and/or by lower alkoxycarbonyl; oxo-lower alkoxy, lower alkoxy, lower alkenyloxy, cycloalkoxy-lower alkoxy, lower alkoxy-lower alkoxy, lower alkoxy-lower alkoxy, lower alkoxy-lower alkoxy, lower alkoxy-lower alkoxy, lower alkoxy, optionally S-oxidised lower alkylthio-lower alkoxy, lower alkylthio-(hydroxy)-lower alkoxy, aryl-lower alkoxy, aryl-lower alkyl, aryl-lower alkoxy, optionally hydrogenated heteroaryl-lower alkoxy, optionally hydrogenated heteroaryl-lower alkoxy or free or esterified or amidated carboxy-lower alkyl;
- R³ and R⁴ are independently hydrogen, halogen, optionally halogenated lower alkyl, hydroxy, optionally halogenated lower alkoxy or cycloalkoxy, lower alkoxy-lower alkyl, cycloalkoxy-lower alkyl, hydroxy-lower alkyl, optionally S-oxidised lower alkylthio-lower alkyl, optionally hydrogenated heteroarylthio-lower alkyl, optionally hydrogenated heteroaryl-lower alkyl; amino-lower alkyl that is unsubstituted or

N-mono- or *N*,*N*-di-lower alkylated, *N*-lower alkanoylated or *N*-lower alkanesulfonylated or *N*,*N*-disubstituted by lower alkylene, by unsubstituted or *N*'-lower alkylene alkylene, by oxa-lower alkylene or by optionally *S*-oxidised thia-lower alkylene, cyano-lower alkyl, free or esterified or amidated carboxy-lower alkyl, cycloalkyl, aryl, hydroxy, lower alkoxy, cycloalkoxy, lower alkoxy, cycloalkoxy-lower alkoxy, hydroxy-lower alkoxy, aryl-lower alkoxy, optionally halogenated lower alkoxy, optionally *S*-oxidised lower alkylthio-lower alkoxy, optionally hydrogenated heteroaryl-lower alkoxy, optionally hydrogenated heteroaryl-lower alkoxy that is unsubstituted or *N*-mono- or *N*,*N*-di-lower alkylated, *N*-lower alkanoylated or *N*-lower alkanoylated or *N*-lower alkylated or *N*'-lower alkylated or *N*'-lower alkanoylated aza-lower alkylene, by oxa-lower alkylene or by optionally *S*-oxidised thia-lower alkylene, cyano-lower alkoxy or free or esterified or amidated carboxy-lower alkoxy; or

- R⁴ together with R₃ is lower alkeneoxy, lower alkylenedioxy or a fused-on aryl, optionally hydrogenated heteroaryl or cycloalkyl ring;
- X is methylene, hydroxymethylene, oxygen, optionally lower alkyl substituted nitrogen, optionally oxidized sulfur;
- R⁵ is lower alkyl or cycloalkyl;
- R⁶ is hydrogen, lower alkyl, hydroxy, alkoxy or halogen;
- R⁷ is unsubstituted or N-mono- or N,N-di-lower alkylated or N-lower alkanoylated amino;
- R8 is lower alkyl, lower alkenyl, cycloalkyl or aryl-lower alkyl;
- R⁹ is optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl-alkyl, cycloalkyl carboxamides, *N* mono or *N*,*N*-dialkyl substituted cycloalkyl carboxamides, optionally substituted aryl-alkyl, optionally substituted aryl-alkyl, optionally substituted aryloxy-aryl, optionally substituted heteroaryloxy-alkyl, free or aliphatically esterified or etherified hydroxy-lower alkyl; amino-lower alkyl that is unsubstituted or *N*-lower alkanoylated or *N*-mono- or *N*,*N*-di-lower alkylated or *N*,*N*-di-substituted by lower alkylene, by hydroxy-, lower alkoxy- or lower alkanoyloxy-lower alkylene, by unsubstituted or *N*'-lower alkanoylated or *N*'-lower alkylene, free or esterified or amidated carboxy-lower alkyl, free or esterified or amidated dicarboxy-lower alkyl,

free or esterified or amidated carboxy-(hydroxy)-lower alkyl, free or esterified or amidated carboxycycloalkyl-lower alkyl, cyano-lower alkyl, lower alkanesulfonyl-lower alkyl, unsubstituted or *N*-mono- or *N*,*N*-di-lower alkylated thiocarbamoyl-lower alkyl, unsubstituted or *N*-mono- or *N*,*N*-di-lower alkylated sulfamoyl-lower alkyl, or a heteroaryl radical bonded *via* a carbon atom and optionally hydrogenated and/or *oxo*-substituted, or lower alkyl substituted by a heteroaryl radical bonded *via* a carbon atom and optionally hydrogenated and/or *oxo*-substituted;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein

R9 is lower alkyl, optionally substituted cycloalkyl (alkyl, OH, alkoxy, alkoxy-alkyl, halogens), optionally substituted cycloalkyl-alkyl (OH, alkoxy, alkoxy-alkyl, halogens on cycloalkyl), cycloalkyl carboxamides, N- mono or N,N-dialkyl substituted cycloalkyl carboxamides, optionally substituted aryl-alkyl, free or aliphatically esterified or etherified hydroxy-lower alkyl; amino-lower alkyl that is unsubstituted or N-lower alkanovlated or N-mono- or N,N-di-lower alkylated or N,N-di-substituted by lower alkylene, by hydroxy-, lower alkoxy- or lower alkanoyloxy-lower alkylene, by unsubstituted or N'-lower alkanoylated or N'-lower alkylated aza-lower alkylene, by oxa-lower alkylene or by optionally S-oxidised thia-lower alkylene, free or esterified or amidated carboxy-lower alkyl, free or esterified or amidated dicarboxy-lower alkyl, free or esterified or amidated carboxy-(hydroxy)-lower alkyl, free or esterified or amidated carboxycycloalkyl-lower alkyl, cyano-lower alkyl, lower alkanesulfonyl-lower alkyl, unsubstituted or N-mono- or N,N-di-lower alkylated thiocarbamoyl-lower alkyl, unsubstituted or N-mono- or N,N-di-lower alkylated sulfamoyl-lower alkyl, or a heteroaryl radical bonded via a carbon atom and optionally hydrogenated and/or oxosubstituted, or lower alkyl substituted by a heteroaryl radical bonded via a carbon atom and optionally hydrogenated and/or oxo-substituted;

- 3. A compound according to claim 2 wherein
 - R¹ and R⁴ are hydrogen;
 - R² is lower alkoxy-lower alkoxy;
 - R³ is halogen or mono, di or tri-halo-substituted alkyl:

WO 2005/051895 PCT/EP2004/013412

- 126 -

- 4. A compound according to claim 3 wherein the halogen/halo is fluorine or chlorine; or a pharmaceutically acceptable salt thereof.
- A compound according to claim 4 wherein
 R³ is fluorine or trifluoromethyl;
 or a pharmaceutically acceptable salt thereof.
- 6. A compound according to claim 5 wherein R² is in the meta position and R³ is in the para position; or a pharmaceutically acceptable salt thereof.
- 7. A compound according to claim 5 wherein R³ is in the ortho position; or a pharmaceutically acceptable salt thereof.
- 8. A compound according to claim 5 wherein R³ is in the meta position; or a pharmaceutically acceptable salt thereof.
- 9. A compound according to claim 2 wherein R² is in the meta position and is lower alkoxy-lower alkoxy optionally substituted by halogen(s); or a pharmaceutically acceptable salt thereof.
- 10. A compound according to claim 9 wherein the halogen(s) is fluorine or chlorine; or a pharmaceutically acceptable salt thereof.
- 11. A compound according to claim 10 wherein the halogen(s) is fluorine; or a pharmaceutically acceptable salt thereof.
- 12. A compound according to claim 9 wherein R³ is lower alkoxy substituted by halogen(s); or a pharmaceutically acceptable salt thereof.
- 13. A compound according to claim 12 wherein the halogen(s) is fluorine or chlorine; or a pharmaceutically acceptable salt thereof.

- 14. A compound according to claim 13 wherein the halogen(s) is fluorine; or a pharmaceutically acceptable salt thereof.
- 15. A compound according to claim 9 wherein R³ is in the para position; or a pharmaceutically acceptable salt thereof.
- 16. A compound according to claim 15 wherein R³ is methoxy; or a pharmaceutically acceptable salt thereof.
- 17. A compound according to claim 15 wherein R³ is trifluoro-methoxy; or a pharmaceutically acceptable salt thereof.
- 18. A compond according to claim 1 wherein
 R³ is located at the para position and is halogen;
 or a pharmaceutically acceptable salt thereof.
- 19. A δ -amino- γ -hydroxy- ω -aryl-alkanoic acid amide compound according to claim 1 having formula (Ia)

wherein

- R¹ is hydrogen, halogen, optionally halogenated alkyl, cycloalkyl, hydroxy, optionally halogenated alkoxy, cycloalkoxy, lower alkoxy-lower alkoxy or free or esterified or amidated carboxy-lower alkoxy or lower alkyl;
- R² is hydrogen, halogen, optionally halogenated lower alkyl, hydroxy, cycloalkyl, cycloalkoxy, optionally halogenated lower alkoxy-lower alkyl, optionally substituted lower alkoxy-lower alkoxy, cycloalkoxy-lower alkyl; optionally lower alkanoylated, halogenated or sulfonylated hydroxy-lower alkoxy; amino-lower alkyl that is unsubstituted or substituted by lower alkyl, by lower alkanoyl and/or by lower alkoxy-

WO 2005/051895

PCT/EP2004/013412

carbonyl; optionally hydrogenated heteroaryl-lower alkyl; amino-lower alkoxy that is substituted by lower alkyl, by lower alkanoyl and/or by lower alkoxycarbonyl; oxo-lower alkoxy, lower alkoxy, lower alkoxy, cycloalkoxy-lower alkoxy, lower alkoxy-lower alkoxy, lower alkoxy-lower alkoxy-lower alkoxy-lower alkoxy-lower alkoxy-lower alkoxy, lower alkoxy, optionally S-oxidised lower alkylthio-lower alkoxy, lower alkylthio-(hydroxy)-lower alkoxy, aryl-lower alkoxy, aryl-lower alkoxy, optionally hydrogenated heteroaryl-lower alkoxy, optionally hydrogenated heteroaryl-lower alkyl, cyano-lower alkoxy, cyano-lower alkyl, free or esterified or amidated carboxy-lower alkyl;

- R³ and R⁴ are independently hydrogen, halogen, optionally halogenated lower alkyl, hydroxy, optionally halogenated lower alkoxy or cycloalkoxy, lower alkoxy-lower alkyl, cycloalkoxy-lower alkyl, hydroxy-lower alkyl, optionally S-oxidised lower alkylthiolower alkyl, optionally hydrogenated heteroarylthio-lower alkyl, optionally hydrogenated heteroaryl-lower alkyl; amino-lower alkyl that is unsubstituted or Nmono- or N,N-di-lower alkylated, N-lower alkanoylated or N-lower alkanesulfonylated or N,N-disubstituted by lower alkylene, by unsubstituted or N'-lower alkylated or N'lower alkanoylated aza-lower alkylene, by oxa-lower alkylene or by optionally Soxidised thia-lower alkylene; cyano-lower alkyl, free or esterified or amidated carboxylower alkyl, cycloalkyl, aryl, hydroxy, lower alkoxy, cycloalkoxy, lower alkoxy-lower alkoxy, cycloalkoxy-lower alkoxy, hydroxy-lower alkoxy, aryl-lower alkoxy, optionally halogenated lower alkoxy, optionally S-oxidised lower alkylthio-lower alkoxy. optionally hydrogenated heteroaryl-lower alkoxy, optionally hydrogenated heteroarylthio-lower alkoxy; amino-lower alkoxy that is unsubstituted or N-mono- or N,N-di-lower alkylated, N-lower alkanoylated or N-lower alkanesulfonylated or substituted by lower alkylene, by unsubstituted or N'-lower alkylated or N'-lower alkanoylated azalower alkylene, by oxalower alkylene or by optionally S-oxidised thia-lower alkylene; cyano-lower alkoxy or free or esterified or amidated carboxy-lower alkoxy; or
- R⁴ together with R₃ is lower alkeneoxy, alkylenedioxy or a fused-on aryl, optionally hydrogenated heteroaryl or cycloalkyl ring;
- X is methylene, hydroxymethylene, oxygen, optionally lower alkyl substituted nitrogen or optionally oxidized sulfur;

- 129 -

PCT/EP2004/013412

R⁵ is lower alkyl or cycloalkyl;

WO 2005/051895

- R⁶ is hydrogen, lower alkyl, hydroxy, alkoxy or halogen;
- R⁷ is unsubstituted or *N*-mono- or *N*,*N*-di-lower alkylated or *N*-lower alkanoylated amino;
- R⁸ is lower alkyl, lower alkenyl, cycloalkyl or aryl-lower alkyl;
- R⁹ is optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl-alkyl, cycloalkyl carboxamides, N- mono or N,N-dialkyl substituted cycloalkyl carboxamides, optionally substituted aryl-alkyl, optionally substituted aryloxy-aryl, optionally substituted heteroaryloxy-alkyl, free or aliphatically esterified or etherified hydroxy-lower alkyl; amino-lower alkyl that is unsubstituted or N-lower alkanoylated or N-mono- or N,N-di-lower alkylated or N,N-di-substituted by lower alkylene, by hydroxy-, lower alkoxy- or lower alkanoyloxy-lower alkylene, by unsubstituted or N'-lower alkanoylated or N'-lower alkylated aza-lower alkylene, by oxa-lower alkylene or by optionally S-oxidised thia-lower alkylene, free or esterified or amidated carboxy-lower alkyl, free or esterified or amidated dicarboxy-lower alkyl, free or esterified or amidated carboxy-(hydroxy)-lower alkyl, free or esterified or amidated carboxycycloalkyl-lower alkyl, cyano-lower alkyl, lower alkanesulfonyl-lower alkyl, unsubstituted or N-mono- or N,N-di-lower alkylated thiocarbamoyl-lower alkyl, unsubstituted or N-mono- or N,N-di-lower alkylated sulfamoyl-lower alkyl, or a heteroaryl radical bonded via a carbon atom and optionally hydrogenated and/or oxosubstituted, or lower alkyl substituted by a heteroaryl radical bonded via a carbon atom and optionally hydrogenated and/or oxo-substituted;

or a pharmaceutically acceptable salt thereof.

- A compound according to claim 19 wherein
 - R⁹ is cycloalkyl substituted with alkyl, hydroxy, alkoxy, alkoxy-alkoxy or halogens; cycloalkyl-alkyl optionally substituted with alkyl, hydroxy, alkoxy, alkoxy-alkoxy or halogens on cycloalkyl or halogens on alkyl or halongens on alkoxy; cycloalkyl carboxamides; N- mono or N,N-dialkyl substituted cycloalkyl carboxamides; or optionally substituted aryl-alkyl;

or a pharmaceutically acceptable salt thereof.

21. A compound according to claim 19 wherein

R⁹ is hydrogen; halogenated alkyl; optionally substituted aryl-alkyl, optionally substituted aryloxy-alkyl, cycloalkyl substituted by 1 to 3 substituents selected from the group consisting of alkenyl, alkynyl, halo, hydroxy, alkoxy, alkoxy-alkoxy, alkylthio, arylthio, aryl-alkoxy, carbamoyl, sulfamoyl, sulfonyl, optionally substituted amino, cyano, carboxy, alkoxycarbonyl, aryl, aryloxy, heterocyclyl or alkyl optionally substituted by amino, halo, hydroxy, alkoxy, carboxy, alkoxycarbonyl, carbamoyl or heterocyclyl; or optionally substituted cycloalkyl-alkyl;

or a pharmaceutically acceptable salt thereof.

22. A compound according to claim 21 wherein

```
R<sup>1</sup> is hydrogen;
```

 R^2 is C_1 - C_4 alkoxy - C_1 - C_4 alkoxy or C_1 - C_4 alkoxy - C_1 - C_4 alkyl;

 R^3 is C_1 - C_4 alkyl or C_1 - C_4 alkoxy;

R⁴ is hydrogen;

X is methylene;

R⁵ is lower alkyl;

R⁶ is hydrogen;

R⁷ is unsubstituted amino;

R⁸ is branched C₃-C₄ alkyl;

R⁹ is optionally substituted cycloalkyl-alkyl;

or a pharmaceutically acceptable salt thereof.

23. A compound according to claim 22 wherein

R² is 3-methoxypropyloxy;

R³ is methoxy;

R⁵ is isopropyl;

R⁸ is isopropyl:

24. The compound of claim 21 wherein

R¹ is hydrogen;

 R^2 is C_1 - C_4 alkoxy - C_1 - C_4 alkoxy or C_1 - C_4 alkoxy - C_1 - C_4 alkyl;

R³ is C₁-C₄ alkyl or C₁-C₄ alkoxy;

R⁴ is hydrogen;

X is methylene;

R⁵ is lower alkyl;

R⁶ is hydrogen;

R⁷ is unsubstituted amino;

R⁸ is branched C₃-C₄ alkyl;

R⁹ is optionally substituted aryl-alkyl; or

a pharmaceutically acceptable salt thereof.

25. A compound according to claim 24 wherein

R² is 3-methoxypropyloxy;

R³ is methoxy;

R⁵ is isopropyl;

R⁸ is isopropyl;

or a pharmaceutically acceptable salt thereof.

- 26. The compound of claim 24 wherein aryl-alkyl is alkyl substituted with phenyl; or a pharmaceutically acceptable salt thereof.
- 27. The compound of claim 26 wherein aryl-alkyl is methyl substituted with phenyl.
- 28. A compound according to claim 27 wherein

R² is 3-methoxypropyloxy;

R³ is methoxy;

R⁵ is isopropyl;

WO 2005/051895 PCT/EP2004/013412

- 132 -

R⁸ is isopropyl;

- 29. A method for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders which method comprises administering a therapeutically effective amount of the compound of claim 1 to a warm-blooded animal in need thereof.
- 30. A pharmaceutical composition comprising the compound of claim 1 and one or more pharmaceutically acceptable excipient(s).
- 31. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a therapeutically effective amount of an anti-diabetic agents, a hypolipidemic agent, an anti-obesity agent or an anti-hypertensive agent.
- 32. A pharmaceutical composition according to claim 30 or 31 for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.
- 33. A pharmaceutical composition according to claim 30 or 31, for use as medicament.
- 34. Use of a pharmaceutical composition according to claim 30 or 31, for the preparation of a medicament for the treatment of conditions associated with renin activity.
- 35. Use of a compound according to claim 1, for the preparation of a pharmaceutical composition for the treatment of conditions associated with renin activity.

WO 2005/051895 PCT/EP2004/013412

- 133 -

- 36. Use according to claim 34 or 35, wherein the condition associated with renin activity is selected from hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.
- 37. A compound according to claim 1, for use as a medicament.